134575-12-5

Basic information

• Product Name: Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester,
• Synonyms: Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester,;exo-6-(Boc-aminomethyl)-3-azabicyclo[3.1.0]hexane;exo-6-(Boc-aminomethyl)-3...;tert-Butyl N-[[(1S,5R)-3-azabicyclo[3.1.0]hexan-6-yl]Methyl]carbaMate;exo-tert-Butyl (3-azabicyclo[3.1.0]hexan-6-ylmethyl)carbamate;tert-butyl N-{[exo-3-azabicyclo[3.1.0]hexan-6-yl]methyl}carbamate
• CAS NO: 134575-12-5
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• Product Categories: N-BOC
• Mol File: 134575-12-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 321.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.064±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.72±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester,(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester,(134575-12-5)
• EPA Substance Registry System: Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester,(134575-12-5)

Safety Data

• Hazardous Substances Data: 134575-12-5(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester, is a chemical compound that is commonly used as a precursor in the synthesis of pharmaceutical drugs and agrochemicals. It is a ester derivative of carbamic acid, and its 3-azabicyclo[3.1.0]hex-6-ylmethyl moiety gives it unique chemical properties that make it useful in various chemical reactions. Carbamic acid, (3-azabicyclo[3.1.0]hex-6-ylmethyl)-, 1,1-dimethylethyl ester, is also known for its potential as a drug target in the treatment of neurological disorders and other medical conditions. Additionally, it is important to handle this chemical with care and in accordance with proper safety protocols due to its potential hazards.

Upstream product

• 134575-11-4 ((1R,5S,6S)-3-Benzyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-carbamic acid tert-butyl ester 
• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 134575-08-9 [1α,5α,6α]-3-Benzyl-3-azabicyclo[3.1.0]hexane-6-carboxaldehyde 
• 134575-10-3 [1α,5α,6α]-6-Aminomethyl-3-benzyl-3-azabicyclo[3.1.0]hexane 
• 134575-07-8 (1α,5α,6α)-6-hydroxymethyl-3-benzyl-3-aza-bicyclo[3.1.0]hexane 

Downstream Products

• 925457-09-6 1-(2,4-difluorophenyl)-7-[(1α,5α,6α)-6-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-3-azabicyclo[3.1.0]hex-3-yl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 392660-08-1 [(1R,5S,6S)-3-(2-Fluoro-4-nitro-phenyl)-3-aza-bicyclo[3.1.0]hex-6-ylmethyl]-carbamic acid tert-butyl ester 
• 392660-16-1 ((1S,5R,6R)-3-{4-[(S)-5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-methyl-carbamic acid tert-butyl ester 
• 392660-13-8 Methanesulfonic acid (R)-3-(4-{(1S,5R,6R)-6-[(tert-butoxycarbonyl-methyl-amino)-methyl]-3-aza-bicyclo[3.1.0]hex-3-yl}-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester 
• 392660-12-7 {(1S,5R,6R)-3-[2-Fluoro-4-((R)-5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-3-aza-bicyclo[3.1.0]hex-6-ylmethyl}-methyl-carbamic acid tert-butyl ester 
• 392660-11-6 (4-{(1S,5R,6R)-6-[(tert-Butoxycarbonyl-methyl-amino)-methyl]-3-aza-bicyclo[3.1.0]hex-3-yl}-3-fluoro-phenyl)-carbamic acid benzyl ester 
• 392660-14-9 {(1S,5R,6R)-3-[4-((R)-5-Azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-aza-bicyclo[3.1.0]hex-6-ylmethyl}-methyl-carbamic acid tert-butyl ester 
• 392660-15-0 {(1S,5R,6R)-3-[4-((S)-5-Aminomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-aza-bicyclo[3.1.0]hex-6-ylmethyl}-methyl-carbamic acid tert-butyl ester 
• 392660-17-2 (S)-N-[[3-[3-fluoro-4-[3-(1α,5α,6α)-6-[[N-methyl]aminomethyl]-3-azabicyclo-[3.1.0]hexane]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide 

Relevant articles and documents

METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.

The synthesis of four new computer-designed fluoroquinolones which have been predicted by QSAR analysis to be active against the protozoa Toxoplasma gondii is described. These compounds are inhibitory in vitro for T. gondii. One of these compounds has a remarkably high activity comparable to that of trovafloxacin. It combines the basic cyclopropyl-quinoline structure of gatifloxacin or moxifloxacin with the C-7 6-amino-3-azabicyclo[3.1.0]hexyl side chain of trovafloxacin. The four compounds are also inhibitory for blood stages of Plasmodium falciparum though at high concentration. These results confirm the potential of quinolones as anti-T. gondii and antimalarial drugs but also show that the QSAR models for T. gondii cannot be reliably extended for screening antimalarial activity.